|
1
|
Cheraghi Z, Poorolajal J, Hashem T,
Esmailnasab N and Irani AD: Effect of body mass index on breast
cancer during premenopausal and postmenopausal periods: A
meta-analysis. PLoS One. 7(e51446)2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Carmichael A: Obesity as a risk factor for
development and poor prognosis of breast cancer. BJOG.
113:1160–1166. 2006.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Carmichael AR and Bates T: Obesity and
breast cancer: A review of the literature. Breast. 13:85–92.
2004.PubMed/NCBI View Article : Google Scholar
|
|
4
|
De Azambuja E, McCaskill-Stevens W,
Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjöld
B, Gutiérez J, Andersson M, et al: The effect of body mass index on
overall and disease-free survival in node-positive breast cancer
patients treated with docetaxel and doxorubicin-containing adjuvant
chemotherapy: The experience of the BIG 02-98 trial. Breast Cancer
Res Treat. 119:145–153. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Guenancia C, Ladoire S, Ghiringelli F,
Rochette L, Vergely C and Cottin Y: Implications of excess weight
in the cardiotoxicity of anthracyclines and trastuzumab in breast
cancer. Arch Cardiovasc Dis. 110:69–71. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Piccart-Gebhart MJ, Procter M,
Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga
J, Bell R, Jackisch C, et al: Trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer. N Engl J Med.
353:1659–1672. 2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Al-Saleh KA, Warith AMA, Altheyab AA,
Afzel A, Abdulaziz N and Ali AM: Effect of weight on drop of
ejection fraction for breast cancer cases receiving trastuzumab. J
Clin Oncol: Conference: 50th Annual Meeting of the
American-Society-of-Clinical-Oncology Vol 32, May 2014.
|
|
8
|
Kosalka P, Johnson C, Turek M, Sulpher J,
Law A, Botros J, Dent S and Aseyev O: Effect of obesity,
dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in
breast cancer. Curr Oncol. 26:e314–e321. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Fasshauer M, Paschke R and Stumvoll M:
Adiponectin, obesity, and cardiovascular disease. Biochimie.
86:779–784. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Maruyama S, Shibata R, Ohashi K, Ohashi T,
Daida H, Walsh K, Murohara T and Ouchi N: Adiponectin ameliorates
doxorubicin-induced cardiotoxicity through Akt protein-dependent
mechanism. J Biol Chem. 286:32790–32800. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Guenancia C, Lefebvre A, Cardinale D, Yu
AF, Ladoire S, Ghiringhelli F, Zeller M, Rochette L, Cottin Y and
Vergely C: Obesity as a risk factor for anthracyclines and
trastuzumab cardiotoxicity in breast cancer: A systematic review
and meta-analysis. J Clin Oncol. 34:3157–3165. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Minichillo S, Gallelli I, Barbieri E,
Cubelli M, Rubino D, Quercia S, Dall'Olio M, Rapezzi C and Zamagni
C: Trastuzumab resumption after extremely severe cardiotoxicity in
metastatic breast cancer patient: A case report. BMC Cancer.
17(722)2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cai F, Luis MAF, Lin X, Wang M, Cai L, Cen
C and Biskup E: Anthracycline-induced cardiotoxicity in the
chemotherapy treatment of breast cancer: Preventive strategies and
treatment. Mol Clin Oncol. 11:15–23. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hendrikx JJ, Haanen JB, Voest EE,
Schellens JH, Huitema AD and Beijnen JH: Fixed dosing of monoclonal
antibodies in oncology. Oncologist. 22:1212–1221. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Dittrich C, Kosty M, Jezdic S, Pyle D,
Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N,
et al: ESMO/ASCO recommendations for a global curriculum in medical
oncology edition 2016. ESMO Open. 1(e000097)2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Plana J, Galderisi M, Barac A, Ewer M, Ky
B and Scherrer-Crosbie M: Expert consensus for multimodality
imaging evaluation of adult patients during and after cancer
therapy: A report from the American Society of Echocardiography and
the European Association of Cardiovascular Imaging. J Am Soc
Echocardiogr. 27:911–939. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Organization World Health: World Health
Organization body mass index (BMI) classification.
|
|
18
|
Perez IE, Taveras Alam S, Hernandez GA and
Sancassani R: Cancer therapy-related cardiac dysfunction: An
overview for the clinician. Clin Med Insights Cardiol: Jul 29, 2019
(Epub ahead of print). doi: 10.1177/1179546819866445.
|
|
19
|
Hodkinson J: Considerations for dosing
immunoglobulin in obese patients. Clin Exp Immunol. 188:353–362.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mohan N, Jiang J, Dokmanovic M and Wu WJ:
Trastuzumab-mediated cardiotoxicity: Current understanding,
challenges, and frontiers. Antib Ther. 1:13–17. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Dong J and Chen H: Cardiotoxicity of
anticancer therapeutics. Front Cardiovasc Med. 5(9)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Florescu M, Cinteza M and Vinereanu D:
Chemotherapy-induced cardiotoxicity. Maedica (Bucur). 8:59–67.
2013.PubMed/NCBI
|
|
23
|
Earl HM, Hiller L, Vallier AL, Loi S,
McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D,
et al: 6 versus 12 months of adjuvant trastuzumab for HER2-positive
early breast cancer (PERSEPHONE): 4-year disease-free survival
results of a randomised phase 3 non-inferiority trial. Lancet.
393:2599–2612. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Jawa Z, Perez RM, Garlie L, Singh M, Qamar
R, Khandheria BK, Jahangir A and Shi Y: Risk factors of
trastuzumab-induced cardiotoxicity in breast cancer: A
meta-analysis. Medicine (Baltimore). 95(e5195)2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Genuino AJ, Chaikledkaew U, The DO,
Reungwetwattana T and Thakkinstian A: Adjuvant trastuzumab regimen
for HER2-positive early-stage breast cancer: A systematic review
and meta-analysis. Expert Rev Clin Pharmacol. 12:815–824.
2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Slamon D and Pegram M: Rationale for
trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin
Oncol. 28 (Suppl 3):S13–S19. 2001.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Perez EA, Suman VJ, Davidson NE, Sledge
GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle
JN, et al: Cardiac safety analysis of doxorubicin and
cyclophosphamide followed by paclitaxel with or without trastuzumab
in the North Central Cancer Treatment Group N9831 adjuvant breast
cancer trial. J Clin Oncol. 26:1231–1238. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Viani GA, Afonso SL, Stefano EJ, De Fendi
LI and Soares FV: Adjuvant trastuzumab in the treatment of
her-2-positive early breast cancer: A meta-analysis of published
randomized trials. BMC Cancer. 7(153)2007.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Abulkhair OA, Saadeddin A, Sedky L, Otaibi
SA and Gasmelseed A: Trastuzumab associated cardiac toxicity: Who
is at risk in Saudi Arabia? A single institution study. Pan Arab J
Oncol. 7:18–22. 2014.
|
|
30
|
Aldiab A: Cardiotoxicity with adjuvant
trastuzumab use in breast cancer: A single institution's
experience. J Saudi Heart Assoc. 22:133–136. 2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Alghafar DA, Younos I, Baimani KA,
Al-Salhi D, Al-Riyami A, Rizvi S and Buckley NE: Trastuzumab
cardiotoxicity in HER2-positive breast cancer patients in tertiary
health care center, sultanate of Oman. J Oncol Pharm Pract.
27:312–321. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Hamed RH, Salim K, Alzahrani A and
Elsamany S: Cardiotoxicity of the adjuvant trastuzumab in a Saudi
population: Clinical experience of a single institution. Forum Clin
Oncol. 7:1–6. 2016.
|
|
33
|
Abdel-Razaq W, Alzahrani M, Al Yami M,
Almugibl F, Almotham M and Alregaibah R: Risk factors associated
with trastuzumab-induced cardiotoxicity in patients with human
epidermal growth factor receptor 2-positive breast cancer. J Pharm
Bioallied Sci. 11:348–354. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kaboré EG, Guenancia C, Vaz-Luis I, Di
Meglio A, Pistilli B, Coutant C, Cottu P, Lesur A, Petit T, Dalenc
F, et al: Association of body mass index and cardiotoxicity related
to anthracyclines and trastuzumab in early breast cancer: French
CANTO cohort study. PLoS Med. 16(e1002989)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Eaton ED and Lyman GH: UptoDate: Dosing of
anticancer agents in adults. last updated: Dec 10, 2021.
|
|
36
|
Griggs JJ, Mangu PB, Temin S and Lyman GH:
Appropriate chemotherapy dosing for obese adult patients with
cancer: American Society of Clinical Oncology clinical practice
guideline. J Oncol Pract. 8:e59–e61. 2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Renehan AG, Harvie M, Cutress RI,
Leitzmann M, Pischon T, Howell S and Howell A: How to manage the
obese patient with cancer. J Clin Oncol. 34:4284–4294.
2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ladoire S, Dalban C, Roché H, Spielmann M,
Fumoleau P, Levy C, Martin AL, Ecarnot F, Bonnetain F and
Ghiringhelli F: Effect of obesity on disease-free and overall
survival in node-positive breast cancer patients in a large French
population: A pooled analysis of two randomised trials. Eur J
Cancer. 50:506–516. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Morrison VA, McCall L, Muss HB, Jatoi A,
Cohen HJ, Cirrincione CT, Ligibel JA, Lafky JM and Hurria A: The
impact of actual body weight-based chemotherapy dosing and body
size on adverse events and outcome in older patients with breast
cancer: Results from Cancer and Leukemia Group B (CALGB) trial
49907 (Alliance A151436). J Geriatr Oncol. 9:228–234.
2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Pan SD, Zhu LL, Chen M, Xia P and Zhou Q:
Weight-based dosing in medication use: What should we know? Patient
Prefer Adherence. 10:549–560. 2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Barras M and Legg A: Drug dosing in obese
adults. Aust Prescr. 40:189–193. 2017.PubMed/NCBI View Article : Google Scholar
|
